Avastin significantly improves survival in metastatic colorectal cancer « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Avastin significantly improves survival in metastatic colorectal cancer

Posted on July 2, 2008 by crimsoncanary

Phase III data presented at the World Congress on Gastrointestinal Cancer show Avastin significantly improves survival in patients with metastatic colorectal cancer irrespective of K-Ras gene mutations

Filed under: kinase | Tagged: Avastin, bevacizumab, Genentech, kinase, Roche, VEGF

« Novartis ALK inhibitor TAE684 effective in some EML4-ALK NSCLC cell lines Amgens Motesanib demonstrates efficacy in Thyroid Cancer »